Altamira Therapeutics Ltd. (NASDAQ:CYTO) has announced the publication of detailed results from its clinical trial with Bentrio nasal spray in house dust mite allergic rhinitis. The study demonstrated statistically significant alleviation of nasal symptoms of allergic rhinitis. The trial enrolled 37 patients in Canada who underwent controlled allergen exposure. The results showed that Bentrio treatment reduced the increase in mean Total Nasal Symptom Score (TNSS) during the 3-hour exposure by 1.1 points vs. no treatment.